---
document_datetime: 2026-02-24 15:50:44
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apixaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apixaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3789434
conversion_datetime: 2026-02-25 11:43:58.68013
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Apixaban Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C.9 Introduction of, or change(s) to, the | 24/02/2026                          |                                             |                                  | To update the RMP of Apixaban Accord to align with |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000324419                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.9.b) Implementation of changes which require additional minor assessment (e.g. change to the due date of obligations and conditions of a marketing authorisation and required pharmacovigilance activities in the risk management plan, including changes to the due date of study milestones, and template updates) - Accepted C.9.b (Type IB) - To update the RMP of Apixaban Accord to align with the RMP of the reference product Eliquis.   |            | the RMP of the reference product Eliquis.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------|
| Variation type IB / EMA/VR/0000321408 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                | 11/02/2026 |                                             |
| Variation type IA / EMA/VR/0000319888 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material,                                                                                                                                                                                                                                                                                 | 22/12/2025 |                                             |

<div style=\"page-break-after: always\"></div>

|                                       | reagent or excipient (when mentioned in the dossier)* - Refused                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IA /                   | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - | 15/12/2025 | EMA/VR/0000316001 |
| Variation type IA / EMA/VR/0000313534 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/12/2025 |                   |
| Variation type IB / EMA/VR/0000269318 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/07/2025 |                   |

<div style=\"page-break-after: always\"></div>

|                                       | authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update Risk Management Plan of Apixaban Accord in line with the EPAR for Risk Management Plan of reference product Eliquis (V. 21.3) published on EMA website on 19-Aug-2024.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000275536 | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet | 16/06/2025 | 18/07/2025 | SmPC, Annex II, Labelling and PL | Extension of indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age for Eliquis (all strengths), As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPCs are updated. The Package Leaflet and Annex II are updated in accordance. The changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/X/0089). To update section 4.8 of the SmPC and section 4 of the PL with information on Anticoagulant-related nephropathy, following assessment of the same change to the reference product Eliquis (EMEA/H/C/PSUSA/00000226/202405). To include a single Patient Alert Card (PAC) combining already approved information for paediatric and adult patients in all boxes, and to update sections 4.2, 4.8(for 5 mg) and 5.2 of the SmPC and section 2 (for 5mg) of the PL to align with editorial changes made to the PI of the reference product. The |

<div style=\"page-break-after: always\"></div>

| changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/IB/0096)   |
|------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                          | (EMEA/H/C/PSUSA/00000226/202405). C.I.2.a - To include a single Patient Alert Card (PAC) combining already approved information for paediatric and adult patients in all boxes, and to update sections 4.2, 4.8(for 5 mg) and 5.2 of the SmPC and section 2 (for 5mg) of the PL to align with editorial changes made to the PI of the reference product. The changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/IB/0096) Additionally, the MAH took the opportunity to update section 4.2, 4.9 and 5.1 of the SmPC and sections 3 and 4 of the PL with editorial changes to align with the PI of the reference product, and updated the contact information of the local representative for   |            |            |                 |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IA / EMA/VR/0000248163    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 03/02/2025 |            |                 |
| Variation type IA_IN / EMA/VR/0000246186 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/01/2025 | 18/07/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|